GABiC proposes the use of biosimilars as strategy for innovation and sustainability

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

GABiC proposes the use of biosimilars as strategy for innovation and sustainability

Home/Reports | Posted 10/09/2021 0 Post your comment

The commitment to biosimilars as a strategy to promote innovation and sustainability is what motivated the creation of the Argentine Quality Biosimilars Group (Grupo Argentino de Biosimilares de Calidad, GABiC) in 2019, made up of the companies Amgen, Gobbi Novag and Sandoz.

Medical Affairs Managers Dr Federico Lipszyc from Amgen and Nicolás Costa from Sandoz explained that the successful introduction of biosimilars in Argentina implies a multidisciplinary effort by laboratories, funders, physicians, auditors and patient associations to offer patients peace of mind and confidence, and that it is essential to educate healthcare professionals about biosimilars, effectively communicate its efficacy and safety, and emphasize the solid scientific evidence that supports biosimilars.

In this regard, GABiC states the need for a multi-sectoral consensus on the concept of sustainability. As studies and publications on the European experience suggest, a sustainable market means that more patients benefit from convenient, timely and reliable access to quality biological therapies.

Competition in biosimilars leads to a long-term predictable cost scheme, without compromising quality and generating savings that can be reinvested in more and better innovative therapies for patients, so not promoting competition in the biosimilars market may impoverish development, eventually leading to higher costs for healthcare systems and patients.

Natalia Jorgensen, Director of the Centre for Health Technology Assessment at ISALUD University (CETSA-ISALUD) and consultant on prioritisation of health interventions at the Inter-American Development Bank (IDB), added that it is difficult to be sustainable if a single instrument is implemented in isolation, so the aim is to have a much more comprehensive drug policy.

Hence, GABiC's objective is to work on multiple fronts, obviously with doctors, who are the ones who will ultimately prescribe these types of molecules, but also involving patients and, undoubtedly, funders.

Country scorecards show biosimilar sustainability

Optimizing the benefits of biosimilars for society

EC workshop on biosimilars focusses on sustainability

LATIN AMERICAN FORUM The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: Conocimiento y percepciones de la denominación de biosimilares en EE. UU. Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: Conocimiento y percepciones de la denominación de biosimilares en EE. UU. Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.